SCHEDULE: Millennium Management Discloses Stake in Phathom Pharmaceuticals

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 4.2% of Phathom Pharmaceuticals, Inc. common stock.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G, indicating their beneficial ownership of Phathom Pharmaceuticals, Inc. common stock.
• The filing, dated June 30, 2026, states that these entities collectively beneficially own 3,375,834 shares, representing 4.2% of the class of securities.
• Millennium Management LLC is identified as the primary reporting person, with shared voting and dispositive power over the shares.
• The filing clarifies that the securities are held by entities subject to the voting control and investment discretion of Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander.
• This filing is an amendment to a previous filing and confirms the current ownership stake.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it confirms a significant institutional investor's stake, but provides no new operational or financial performance data.

Positives

• Confirmation of a significant institutional investor (Millennium Management) holding a stake in Phathom Pharmaceuticals.
• The 4.2% ownership stake indicates a notable level of confidence from a well-established investment firm.

Negatives

• The filing does not provide details on the acquisition cost or the specific investment strategy behind this stake.
• No forward-looking statements or specific performance targets are included in this ownership disclosure.

Risks

• Potential for future changes in ownership by Millennium Management, which could impact share price.
• The concentration of voting and dispositive power within Millennium Management could influence corporate actions.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or specific guidance regarding Phathom Pharmaceuticals' future performance.

Management Comments

• "The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that significant filings by large investment management firms like Millennium Management often signal conviction in a company's long-term prospects or a strategic re-evaluation of its position within the biotechnology sector.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's interest, which can be viewed positively, but also introduces potential for future trading activity by this entity.
• Management and Board: The presence of a large shareholder may influence strategic decisions and governance discussions.

Next Steps

• Monitor future filings from Millennium Management for any changes in ownership.
• Observe Phathom Pharmaceuticals' operational and financial performance for insights into the investment thesis.

Key Dates

Recommendation

The filing indicates a significant institutional holding but does not provide new operational or financial data to warrant a strong buy or sell recommendation. It confirms existing interest and suggests a 'hold' stance pending further company performance updates.

Keywords

Phathom Pharmaceuticals, Millennium Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management